Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Price:
9.18 USD
0.88%
Market Closed
Updated:
Apr 27, 2024
Phathom Pharmaceuticals Inc
Net Income (Common)
|
Phathom Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Net Income (Common)
-$201.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-175%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$40.6B
|
CAGR 3-Years
39%
|
CAGR 5-Years
23%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$2.1B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-21%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$365m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-22%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$5.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
1%
|
See Also
What is Phathom Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-201.6m
USD
-201.6m
USD
Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Net Income (Common) amounts to -201.6m USD.
What is Phathom Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-175%
-175%
Over the last year, the Net Income (Common) growth was -2%. The average annual Net Income (Common) growth rates for Phathom Pharmaceuticals Inc have been -16% over the past three years , -175% over the past five years .
You don't have any saved screeners yet
